#news #biotech Supernus’ stocks down once more, despite positive phase 3 ADHD data for SPN-812

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Supernus’ stocks down once more, despite positive phase 3 ADHD data for SPN-812 .Supernus’ topline results from two phase 3 studies of children with ADHD hit their primary endpoints but didn’t wow investors worried about how its nonstimulant treatment will take on established generics.

from FierceBiotech: Biotech https://ift.tt/2Ul04fc